Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Neuroone Medical Technologies (NMTC) over the last 11 years, with Q4 2025 value amounting to -$619376.0.

  • Neuroone Medical Technologies' Change in Accured Expenses fell 3369.02% to -$619376.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$210526.0, marking a year-over-year decrease of 39441.73%. This contributed to the annual value of -$54442.0 for FY2025, which is 43577.16% down from last year.
  • According to the latest figures from Q4 2025, Neuroone Medical Technologies' Change in Accured Expenses is -$619376.0, which was down 3369.02% from $302463.0 recorded in Q3 2025.
  • In the past 5 years, Neuroone Medical Technologies' Change in Accured Expenses registered a high of $1.7 million during Q3 2022, and its lowest value of -$1.4 million during Q1 2023.
  • Its 5-year average for Change in Accured Expenses is -$28344.6, with a median of $53193.5 in 2025.
  • In the last 5 years, Neuroone Medical Technologies' Change in Accured Expenses surged by 122796.65% in 2022 and then plummeted by 744794.02% in 2023.
  • Quarter analysis of 5 years shows Neuroone Medical Technologies' Change in Accured Expenses stood at -$317456.0 in 2021, then rose by 3.57% to -$306125.0 in 2022, then crashed by 69.4% to -$518584.0 in 2023, then rose by 10.66% to -$463292.0 in 2024, then crashed by 33.69% to -$619376.0 in 2025.
  • Its Change in Accured Expenses was -$619376.0 in Q4 2025, compared to $302463.0 in Q3 2025 and $73839.0 in Q2 2025.